Grading and Staging of Tumors

Slide 1 · Grading and Staging

of Tumors

Morphologic aggressiveness, anatomic extent, and clinical interpretation

A morphology-to-clinical-extent framework

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Explain why tumor grade and stage answer different clinical questions.

Identify the morphologic features used to assess differentiation.

Interpret the general T, N, and M axes without inventing site-specific cutoffs.

Recognize limitations of morphologic grading, sampling, and purely anatomic staging.

Slide 3 · Why assign grade and stage?

Estimate likely clinical behavior

Prognostic interpretation

Characterize tumor extent

Clinical burden

Compare treatments fairly

Comparable patient groups

Slide 4 · Two complementary axes

GRADE — tumor phenotype

How closely neoplastic cells resemble normal tissue

Architectural, cytologic, and sometimes proliferative findings

A morphologic estimate of aggressiveness

STAGE — disease extent

Primary lesion and local spread

Regional lymph-node involvement

Distant metastatic dissemination

Slide 5 · Biologic appearance is not anatomic spread

Histologic appearance ↓

Less extensive disease

More extensive disease

More differentiated

Localized, differentiated tumor

Disseminated, differentiated tumor

Less differentiated

Localized, anaplastic tumor

Disseminated, anaplastic tumor

Anatomic spread →

Slide 6 · Two different risks

Localized, well-differentiated thyroid cancer

Cells resemble thyroid tissue

Anatomic extent remains confined

Differentiation and spread both matter

Anaplastic thyroid cancer invading adjacent tissues

Poor morphologic differentiation

Extension into surrounding structures

Clinical course cannot be inferred from a single feature

Slide 7 · Grade describes tumor-cell differentiation

Differentiation is resemblance to normal parenchymal cells.

Resemblance is judged morphologically and sometimes functionally.

Grading converts selected tissue features into a prognostic descriptor.

The exact features and category boundaries depend on tumor type.

Slide 8 · Differentiation forms a continuum

Well differentiated

Recognizable parent-tissue pattern

Moderately differentiated

Partial preservation of tissue pattern

Poorly differentiated / anaplastic

Marked loss of normal phenotype

Slide 9 · Well-differentiated tumors retain structure

Simplified schematic — not histologic evidence

Relatively uniform cells preserve a recognizable tissue pattern.

Some cancers form structures resembling their site of origin.

Morphologic resemblance alone does not exclude malignancy.

Slide 10 · Moderate differentiation preserves partial pattern

Simplified schematic — not histologic evidence

Tumor still forms some recognizable structures.

Architecture is more irregular than its normal counterpart.

Invasion, not differentiation alone, establishes malignant behavior.

Slide 11 · Poor differentiation obscures lineage morphology

Simplified schematic — not histologic evidence

Normal architectural organization is largely lost.

Cellular and nuclear atypia may be conspicuous.

Precise tumor classification may require ancillary studies.

Slide 12 · Anaplasia is loss of differentiation

DIFFERENTIATED

Organized tissue-like structure

Some specialized functions may remain

Normal counterparts are recognizable

ANAPLASTIC

Disordered appearance

Numerous atypical cell features

Tissue of origin can be difficult to recognize

Slide 13 · Architecture can contribute to grade

Assess gland formation or other tissue-appropriate structures.

Ask whether the neoplasm respects normal cellular relationships.

Architecture is one component—not a universal standalone grade.

Each organ-specific grading system defines its own relevant patterns.

Slide 14 · Pleomorphism reflects morphologic diversity

Simplified schematic — not histologic evidence

Cells vary in size and shape within the same lesion.

Tumor giant cells may be present in markedly anaplastic neoplasms.

Pleomorphism contributes to atypia but is not itself a staging variable.

Slide 15 · Abnormal nuclear features support anaplasia

Nuclei may become disproportionately large.

Nuclear outlines and chromatin distribution may be irregular.

Hyperchromasia and conspicuous nucleoli may be present.

Interpret nuclear features in tissue and tumor-type context.

Slide 16 · Mitotic activity informs selected grading systems

Frequent mitoses can reflect active tumor proliferation.

Atypical mitoses strengthen evidence of malignant cytology.

Mitoses also occur in normal regenerating or hyperplastic tissue.

No universal mitotic-count threshold applies across all cancers.

Slide 17 · Mitosis and malignancy are not synonyms

A mitotic figure

Observed during normal tissue turnover

May accompany repair or hyperplasia

Requires clinical and histologic context

An atypical mitosis

May show abnormal spindle geometry

Can be seen in highly anaplastic tumors

Supports atypia but does not define TNM stage

Slide 18 · Loss of polarity indicates architectural disorder

Basement membrane

Stromal compartment

Disrupted alignment and polarity

Simplified schematic — not histologic evidence

Normal epithelial cells have organized orientation.

Anaplastic cells may lose coordinated alignment.

The architectural disruption is separate from distant spread.

Slide 19 · Ischemic necrosis can accompany rapid growth

Tumor expands

Increasing tissue demand

Stromal vasculature is inadequate

Relative ischemia

Necrosis develops

Region of nonviable tumor

Slide 20 · Specialized function may track differentiation

Preserved function

Some thyroid tumors form follicles

Differentiated squamous cancers may form keratin

Endocrine tumors may still secrete hormones

Lost or altered function

Poorly differentiated tumors may lose mature functions

Some cancers acquire unexpected secretory properties

Function alone does not establish stage

Slide 21 · Grade is not a universal numerical scale

Grading pattern

Source-supported principle

Interpretation

Two-tier

Low grade / high grade

Broad qualitative separation

More categories

Up to four categories described

Finer morphologic stratification

Across tumor types

Criteria differ by organ and neoplasm

Do not transfer thresholds

Slide 22 · The same appearance can have different meaning

Grade definitions are tailored to the biology of each malignancy.

Gland architecture may matter in one tumor, mitoses in another.

Specific grading criteria cannot be extrapolated from unrelated organs.

The generic Robbins framework does not supply organ-specific thresholds.

Slide 23 · A descriptive diagnosis can be more defensible

Morphologic description

“Well differentiated” or “poorly differentiated”

Record tissue and tumor type

State conspicuous diagnostic features

Formal grade

Use only the applicable validated grading framework

Avoid spurious precision where no scheme is supplied

Do not fabricate a numerical category

Slide 24 · Grade predicts behavior imperfectly

Microscopic phenotype

A useful biologic clue

Other tumor/host variables

Additional influences on course

Observed outcome

Not guaranteed by morphology alone

Slide 25 · Differentiation does not prove benignity

Well-differentiated carcinoma

May closely mimic normal cells

Can still invade adjacent tissue

May metastasize

Benign neoplasm

Usually well differentiated

Lacks malignant invasive/metastatic capacity

Grade cannot substitute for diagnosis

Slide 26 · Invasion is a distinct morphologic question

Basement membrane

Stromal compartment

Invasive focus

Basement-membrane interruption

Simplified schematic — not histologic evidence

A tumor may look highly differentiated yet invade stroma.

A preserved basement membrane separates in situ from invasive epithelium.

Invasion must not be inferred merely from cytologic atypia.

Slide 27 · Dysplasia is not tumor grade

Dysplasia

Disordered epithelial growth

May be a precursor to malignancy

Progression is not inevitable

Cancer grading

Characterizes an established malignancy

Describes morphologic differentiation

Applied through tumor-specific systems

Slide 28 · Carcinoma in situ is noninvasive

Basement membrane

Stromal compartment

No tumor cells beneath boundary

Simplified schematic — not histologic evidence

Severe epithelial atypia may involve the full thickness.

Basement membrane remains intact.

An in situ lesion is not equivalent to stromal invasion.

Slide 29 · Biopsy may sample only part of the tumor

Heterogeneous mass

Different regions may differ

Limited tissue sample

Partial representation

Assigned morphologic grade

Must respect sampling uncertainty

Slide 30 · Tumor-center necrosis reduces useful sampling

Tumor center

May contain ischemic necrosis

Can yield nonviable material

May obscure architecture

Viable representative tissue

Preserves cellular morphology

Improves architectural evaluation

Requires suitable handling

Slide 31 · The specimen determines what can be evaluated

Material

Strength

Interpretive limitation

Resection

Broad architecture and extent

Availability depends on treatment

Core/incisional biopsy

Tissue architecture in sampled region

May underrepresent heterogeneity

Cytology/FNA

Cell-level atypia

Cannot reliably demonstrate tissue invasion

Slide 32 · Cytology does not directly establish invasion

Cytologic preparations primarily show individual cells or clusters.

Cellular atypia can suggest malignancy and altered differentiation.

The tissue boundary needed to demonstrate invasion may be absent.

Distinguish cytologic impression from full histologic assessment.

Slide 33 · Morphologic grading requires technical quality

Representative acquisition

Adequate viable tissue

Proper preservation

Usable cellular detail

Microscopic interpretation

Applicable tumor-specific framework

Slide 34 · What grade does—and does not—say

Grade informs

Grade alone cannot establish

Differentiation and selected atypical features

Regional node status

Sometimes proliferation and architecture

Presence of distant metastasis

An estimate of tumor aggressiveness

Precise clinical outcome for an individual

Slide 35 · Stage summarizes anatomic disease extent

Staging examines the primary lesion, regional lymph nodes, and metastases.

It aims to quantify the apparent spread at assessment.

The result supports prognosis and comparison of treatment outcomes.

For solid cancers, TNM provides a structured language.

Slide 36 · TNM describes three separate dimensions

T

Primary lesion — size and/or local extent

N

Regional lymph-node involvement

M

Distant metastatic disease

Slide 37 · T refers to the primary lesion

Primary cancer

Originating site

Tumor size and local extent

Assess site-specific parameters

T descriptor

Anatomic primary category

Slide 38 · T categories are cancer-specific

T1–T4 as categories of increasing primary-tumor burden.

Size and local extension must be interpreted by cancer site.

An identical dimension need not imply an identical T category in two organs.

Do not assign formal T categories without the site-specific staging manual.

Slide 39 · Tumor size is not its entire biological story

Smaller primary tumor

May still possess aggressive cytology

Metastasis can sometimes occur

Size alone does not determine grade

Larger primary tumor

May show relatively differentiated cells

Local invasion can affect resectability

Size alone does not prove metastasis

Slide 40 · Local invasion complicates complete excision

Basement membrane

Stromal compartment

Invasive focus

Basement-membrane interruption

Simplified schematic — not histologic evidence

Malignant growth may cross normal tissue boundaries.

Tumor margins can be irregular or microscopically infiltrative.

An apparently circumscribed cancer may still invade.

Slide 41 · Anatomic depth differs from cytologic grade

Depth / extent

Where the tumor has reached

Whether adjacent structures are infiltrated

A question for local tumor assessment

Cytologic grade

How tumor cells and architecture look

Degree of differentiation

A biologic morphology descriptor

Slide 42 · N refers to regional lymph nodes

Primary lesion

Source of potential lymphatic spread

Regional drainage basin

Route to regional nodes

N descriptor

Evidence of nodal involvement

Slide 43 · Lymphatic spread commonly begins regionally

Carcinomas commonly disseminate first through lymphatics.

Routes often follow the ordinary regional drainage pathways.

Regional spread is not synonymous with hematogenous metastasis.

Unusual drainage and skip metastases can occur.

Slide 44 · A sentinel node samples first-echelon drainage

Primary tumor

Lymphatic drainage

Sentinel lymph node

First receiving regional node

Microscopic assessment

Evidence of spread

Slide 45 · An enlarged node is not necessarily malignant

Reactive enlargement

Tumor antigens may provoke nodal immune responses

Size can increase without tumor deposits

Clinical impression is not tissue proof

Metastatic involvement

Tumor cells present in nodal tissue

Histologic examination can establish involvement

N interpretation needs relevant nodal evidence

Slide 46 · N categories encode regional involvement

N0 indicates no regional nodal involvement in the source framework.

N1–N3 represent increasing nodal disease by applicable system.

The involved number, range, or stations are cancer-dependent.

A generic N label is not a substitute for organ-specific rules.

Slide 47 · M records distant metastatic disease

No identified distant metastasis

No distant deposits established in the assessment

Notation depends on formal staging rules

Do not equate absence of evidence with a guaranteed absence

Distant metastasis identified

Cancer found at a physically discontinuous site

Defines systemic spread for many solid cancers

Major clinical and prognostic consequence

Slide 48 · Blood-borne metastases extend beyond the primary region

Vascular invasion

Tumor enters circulation

Transport and arrest

Distant capillary bed

Colonization

Metastatic deposit

Slide 49 · Metastatic pattern follows anatomy and biology

Venous drainage influences where circulating tumor cells arrest.

Liver and lungs are common sites of hematogenous deposits.

Organ-specific tumor biology influences metastatic distribution.

The presence of metastasis is not predicted perfectly by grade.

Slide 50 · Serosal seeding is another route of spread

Tumor breaches surface

Access to a body cavity

Cells seed cavity surfaces

Discontinuous implantation

Disseminated deposits

Further anatomic tumor burden

Slide 51 · Invasion and metastasis are separable

Locally invasive, rarely metastatic

Some malignant tumors infiltrate despite few distant deposits

Local progression still matters clinically

Do not equate invasion with inevitable M1

Distant metastatic tumor

Cells have spread to discontinuous sites

Can occur despite an initially small primary

M status must be assessed directly

Slide 52 · T, N, and M should not be collapsed early

T

Record the primary-site extent

N

Record regional nodal evidence

M

Record distant spread evidence

Slide 53 · TNM components require site-specific synthesis

Descriptor

What it describes

What it is not

T

Extent of the primary cancer

A universal size cutoff

N

Regional nodal spread

Any lymph-node enlargement

M

Distant metastatic spread

A surrogate for histologic grade

Slide 54 · Grading and TNM answer different questions

Histologic appearance ↓

Limited anatomic extent

Extensive anatomic spread

More differentiated

Low morphologic atypia; Limited spread

Low morphologic atypia; Extensive spread

Less differentiated

High morphologic atypia; Limited spread

High morphologic atypia; Extensive spread

Anatomic spread →

Slide 55 · Stage is generally more clinically useful

Stage over grade in broad prognostic value.

Anatomic spread strongly influences the possibility of definitive control.

The same grade may occur with different extent of disease.

Grade still contributes useful independent morphologic information.

Slide 56 · Clinical assessment and tissue findings complement

Imaging / clinical evaluation

Estimates extent and distant disease

Helps identify involved structures

Cannot always determine microscopic spread

Surgical / pathologic assessment

Can directly examine sampled tumor and nodes

Documents tissue infiltration

Limited by what has been removed or sampled

Slide 57 · Unexamined tissue creates classification limits

Sampling is incomplete

Unobserved anatomic compartments

Extent is uncertain

Evidence does not justify precision

Report limitations clearly

Avoid unsupported TNM claims

Slide 58 · Anatomic staging needs diagnostic context

Confirm the nature of the primary malignancy.

Interpret local spread in the correct organ context.

Distinguish regional from distant sites using the relevant definitions.

Use the appropriate site-specific staging rules for a formal assignment.

Slide 59 · Grade and stage must appear separately in reports

Diagnostic dimension

Typical report content

Potential error

Tumor diagnosis

Type and site of malignancy

Replacing diagnosis with grade

Grade

Histologic differentiation / system

Using generic grading thresholds

Extent / TNM

Anatomic primary, nodal, metastatic data

Inferring missing components from grade

Slide 60 · Morphology and anatomy do not explain all risk

Histologic grade

Morphologic risk signal

TNM stage

Anatomic burden

Tumor molecular features

Complementary prognosis

Slide 61 · Molecular tumor features can add prognosis

Molecular information as complementary to anatomic staging.

Molecular prognostic information can be independent of apparent spread.

The textbook uses selected early breast cancers as an example.

No specific assay or biomarker thresholds are prescribed in this excerpt.

Slide 62 · Early breast cancer illustrates multimodal assessment

Anatomic description

T1–2, N0, M0 is the textbook example

Molecular characterization

May refine prognostic evaluation

Interpretation

Combined information is preferable to one axis alone

Slide 63 · A prognostic biomarker is not a TNM category

Molecular or biologic feature

Can help stratify likely outcome

May add information beyond stage

Requires validated disease-specific interpretation

Anatomic descriptor

Records primary, regional, and distant extent

Must follow staging definitions

Does not by itself reveal every biological feature

Slide 64 · Do not silently modernize staging criteria

TNM manuals and disease-specific categories can change.

This lecture teaches the general framework in the supplied Robbins text.

Exact numeric size cutoffs and stage groups are intentionally omitted.

Formal contemporary case staging requires current site-specific authority.

Slide 65 · Case exercise: Differentiated tumor with spread

CLINICAL STEM

A biopsy shows recognizable gland formation. Imaging identifies deposits at a discontinuous distant site.

DISCUSSION PROMPTS

Which evidence informs grade?

Which evidence informs metastatic status?

Can an apparently differentiated carcinoma be metastatic?

Slide 66 · Case interpretation: Appearance does not cancel metastasis

Grade evidence

Gland formation suggests retained differentiation

Stage evidence

Distant deposits establish dissemination

Core principle

Morphologic differentiation does not preclude metastasis

Slide 67 · Case exercise: Marked atypia, apparently localized

CLINICAL STEM

A resected tumor is highly pleomorphic, with abnormal mitoses. Available assessment finds no nodal or distant tumor.

DISCUSSION PROMPTS

What findings describe its phenotype?

What data describe extent?

Should a numeric stage group be assigned here?

Slide 68 · Case interpretation: Phenotype is not extent

Grade evidence

Pleomorphism and atypical mitoses

Stage evidence

Extent depends on primary, nodes, metastases

Limitation

No formal TNM category without site-specific data

Slide 69 · Case exercise: Palpable regional lymph node

CLINICAL STEM

An individual with carcinoma has an enlarged regional draining lymph node. The node has not been sampled.

DISCUSSION PROMPTS

Does enlargement itself establish nodal metastasis?

What other explanation can account for enlargement?

What finding would improve N assessment?

Slide 70 · Case interpretation: Nodal enlargement is ambiguous

Observation

The node is enlarged

Competing explanation

Reactive immune hyperplasia

Needed evidence

Examination for tumor deposits, as clinically indicated

Slide 71 · Five distinctions that prevent staging errors

Do not confuse

With

Differentiation

Anatomic spread

Atypical mitoses

Evidence of metastasis

In situ growth

Stromal invasion

Enlarged regional node

Proven nodal metastasis

Molecular prognosis

A universal TNM substitute

Slide 72 · Reporting checklist for a solid malignancy

Identify the tumor type and origin.

Use a defensible tumor-specific histologic grade when applicable.

Document primary extent and available regional nodal findings.

Record distant spread evidence and unresolved assessment limits.

Keep molecular prognostic information distinguishable from anatomy.

Slide 73 · Clinical synthesis: Three distinct information layers

What is it?

Diagnosis / lineage / differentiation

Where is it?

Primary extent, nodes, distant sites

How might it behave?

Integrated morphology, anatomy, molecular features

Slide 74 · Consolidation questions

Why can a well-differentiated carcinoma still have a poor prognosis?

How do mitoses contribute to some—but not all—grading systems?

What additional information is needed beyond tumor size?

Why is a single regional node enlargement not automatically N-positive?

Slide 75 · Source and interpretation notes

Robbins, Cotran & Kumar: Pathologic Basis of Disease. 11th ed. (2026). Chapter 7: Neoplasia.

Principal section: “Grading and Staging of Tumors,” pp. 295–296.

Adjacent context: “Differentiation and Anaplasia,” pp. 239–241; invasion/metastasis, pp. 241–244.

Associated clinical/laboratory context: “Histologic and Cytologic Methods,” pp. 296–297.

Formal site-specific TNM criteria are not reproduced; consult the relevant current staging manual before clinical use.